首页|氯吡格雷联合阿司匹林对急性脑梗死患者机体血清hs-CRP、IL-6、CTRP3水平的影响

氯吡格雷联合阿司匹林对急性脑梗死患者机体血清hs-CRP、IL-6、CTRP3水平的影响

Effect of clopidogrel combined with aspirin on serum hs-CRP,IL-6 and CTRP3 levels in patients with acute cerebral infarction

扫码查看
目的:探究氯吡格雷联合阿司匹林(ASP)对急性脑梗死(ACI)患者机体血清高敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子相关蛋白3(CTRP3)水平的影响.方法:回顾我院90例ACI患者(2022年1月-2023年12月)资料,按治疗方案不同分成A组(n=45)、B组(n=45).A组接受氯吡格雷联合ASP治疗,B组接受ASP治疗.对比2组总有效率、治疗前后美国国立卫生研究院卒中量表(NIHSS)、蒙特利尔认知评估量表(MoCA)评分、血液流变学[全血低切黏度(LBV)、全血中切黏度(WBV)、全血高切黏度(HBV)、血浆黏度(PV)]、神经损伤因子[神经元特异性烯醇化酶(NSE)、基质金属蛋白酶-9(MMP-9)、中枢神经特异蛋白(S-100β)]、血清hs-CRP、IL-6、CTRP3水平、不良反应发生率.结果:A组总有效率93.33%(42/45)较B组75.56%(34/45)显著增高(P<0.05);治疗14d后A组NIHSS评分较B组低,MoCA评分较B组高(P<0.05);治疗14d后A组LBV、WBV、HBV、PV水平较B组低(P<0.05);治疗14 d后A组血清NSE、MMP-9、S-100β水平较B组低(P<0.05);治疗14d后A组血清hs-CRP、IL-6水平较B组低,血清CTRP3水平较B组高(P<0.05);2组不良反应发生率相比无明显差异(P>0.05).结论:氯吡格雷联合ASP治疗ACI患者效果显著,可有效缓解机体炎性状态,减轻神经损伤,调节血流流变学水平,改善神经及认知功能,且具有较高用药安全性.
Objective:To investigate the effect of clopidogrel combined with aspirin(ASP)on serum high-sensitivity C-reactive protein(hs-CRP),interleukin-6(IL-6),and tumour necrosis factor-related protein 3(CTRP3)levels in patients with acute cerebral infarction(ACI).Methods:-90 ACI patients were collected(from January 2022 to December 2023)in our hospital and divided into group A(n=45)and group B(n=45)according to treatment regimen.Group B received ASP treatment,while group A received clopidogrel combined with ASP treatment.Compare the total effective rate and levels of the National Institutes of Health Stroke Scale(NIHSS),Montreal Cognitive Assessment Scale(MoCA),hemorheology[whole blood low cut viscosity(LBV),whole blood mid cut viscosity(WBV),whole blood high cut viscosity(HBV),plasma viscosity(PV)],nerve injury factors[neuron-specific enolase(NSE),matrix metalloproteinase-9(MMP-9),central nervous system-specific protein(S-100β)],serum high sensitivity C-reactive protein(hs-CRP),interleukin-6(IL-6),tumor necrosis factor associated protein 3(CTRP3)before and after treatment between the two groups,as well as the incidence of adverse reactions during treatment.Results:The total effective rate of group A was 93.33%(42/45)higher than group B 75.56%(34/45)(P<0.05);NIHSS score was lower and MoCA score was higher in group A than in group B after 14 d of treatment(P<0.05);LBV,WBV,HBV,PV levels were lower in group A than in group B after 14 d of treatment(P<0.05);Serum NSE,MMP-9,S-100β expression was lower in group A than in group B after 14 d of treatment(P<0.05).The expression of serum NSE,MMP-9 and S-100β in group A was lower than that in group B after 14 d of treatment(P<0.05);After 14 days of treatment,the serum levels of hs CRP and IL-6 in group A were lower than those in group B,while the serum levels of CTRP3 were higher than those in group B(P<0.05);There was no significant difference in the incidence of adverse reactions between the 2 groups compared with each other(P>0.05).Conclusion:The combination of clopidogrel and ASP has a significant effect on treating ACI patients,which can effectively alleviate the inflammatory state of the body,reduce nerve damage,regulate blood theology levels,improve neurological and cognitive functions,and has high drug safety.

Acute cerebral infarctionClopidogrelNeurological damage factor

赵芳芳、张建磊、史宗霖、张颖、常娜

展开 >

河南大学淮河医院神经内科,河南开封 475000

急性脑梗死 氯吡格雷 神经损伤因子

2024

医学检验与临床
山东省千佛山医院

医学检验与临床

影响因子:0.294
ISSN:1673-5013
年,卷(期):2024.35(11)